Therapeutic Outcomes of Papillary Thyroid Cancer Patients in Different Risk Groups

Publisher： Karger

E-ISSN： 1423-0232|80|1-2|123-129

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.1-2, 2011-06, pp. : 123-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CHEK2 mutations and the risk of papillary thyroid cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 3, 2015-08 ,pp. : 548-552

John Wiley & Sons Inc

Access to resources Recommend Favorite

A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low‐risk papillary thyroid cancer patients: implication for radioiodine indication

By  

CLINICAL ENDOCRINOLOGY, Vol. 83, Iss. 6, 2015-12 ,pp. : 957-961

John Wiley & Sons Inc

Access to resources Recommend Favorite

Scoring Patients’ Risk in Differentiated Thyroid Cancer

By  

Oncology Research and Treatment, Vol. 24, Iss. 6, 2002-01 ,pp. : 561-568

Karger

Access to resources Recommend Favorite

Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis

By  

BRITISH JOURNAL OF SURGERY, Vol. 105, Iss. 3, 2018-02 ,pp. : 270-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness analysis of papillary thyroid cancer surveillance

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4132-4140

John Wiley & Sons Inc

Access to resources Recommend Favorite